Cardiology in Colorado

Double Black Imaging Corporation manufactures and integrates medical displays, monitors, and calibration software for diagnostic imaging, radiology, and surgical applications. Founded over 20 years ago, DBI specializes in PACS displays (3MP–12MP), mammography/tomosynthesis multi-modality monitors, surgical OR displays (26"–58"), clinical review displays, MR-Safe monitors, dental displays, and non-destructive testing (NDT) LED displays. The company develops proprietary DICOM calibration software (X-CAL® and CFS suites) and performs 100% display system integration and software development in the USA. DBI offers comprehensive product bundles including ergonomic workstations (66+ configurations), mounting solutions, CPUs, and DICOM laptops tailored for radiology departments and teleradiology operations. The company integrates LG Medical displays with proprietary calibration software under long-term licensing agreements. All displays are DICOM-calibrated and hospital-grade, backed by installation, training, and technical support. DBI serves radiology departments, surgical centers, dental practices, and imaging enterprises worldwide, emphasizing reliability, image quality stability, and cost reduction. The company maintains a track record of serving thousands of radiologists and IT professionals with industry-leading customer service.

Terumo BCT, Inc. is a division of Terumo Corporation and a global leader in blood management, blood and cell therapies, and related healthcare solutions. Headquartered in Lakewood, Colorado, Terumo BCT operates as the Blood Management Company within the Terumo Group, serving over 130 countries and regions worldwide. The company develops, manufactures, and distributes medical devices and consumables for blood transfusion management, hemapheresis, cell therapy processing, and related clinical applications. Terumo BCT specializes in automated blood collection, processing, testing, and therapeutic apheresis technologies. The company's product portfolio includes blood management systems, cell and gene therapy manufacturing solutions, and diagnostic equipment for blood banking and transfusion medicine. Terumo BCT maintains regulatory compliance with FDA, ISO 13485, and CE marking requirements. The company operates manufacturing facilities in North America and maintains a robust distribution and service infrastructure supporting hospitals, blood banks, and healthcare institutions globally. As part of the larger Terumo Group, which generated approximately 35% of group sales from North American operations, Terumo BCT represents a significant strategic asset in cellular and blood-based therapeutic innovation and clinical implementation.

Corcym is a global medical device company specializing in structural heart disease, with expertise in heart valve prostheses and cardiac repair devices. The company manufactures a comprehensive portfolio of products including sutureless aortic valves (Perceval), mechanical heart valves (Carbomedics, Bicarbon, Orbis families), bioprosthetic aortic valves (CarboSeal Valsalva), and annuloplasty rings for mitral and tricuspid valve repair (Memo platform, Sovering flexible rings, HAART, TriMemo). Products are supported by solid clinical evidence and designed for surgical precision in structural heart interventions. Corcym holds FDA clearances (including recent TriMemo clearance in 2026 for tricuspid repair) and maintains regulatory approvals in multiple markets including China. The company provides healthcare professional education through Corcym Academy, offering training programs in aortic valve replacement with Perceval, annuloplasty techniques with Memo 4D, minimally invasive approaches, and robotic-assisted procedures. Corcym serves cardiac surgeons and heart surgery centers globally, with patient support programs, investigator-initiated research collaboration, and comprehensive product safety and device tracking systems. The organization emphasizes innovation in minimally invasive cardiac surgery and peer-to-peer clinical knowledge exchange through partnerships with scientific societies.

Corgenix Medical Corporation is a CAP/CLIA-accredited in vitro diagnostics (IVD) company founded in 1990 and based in Broomfield, Colorado. The company specializes in developing, manufacturing, and commercializing diagnostic kits and operates as a Contract Development and Manufacturing Organization (CDMO) serving biotech companies, pharmaceutical firms, cancer centers, and academic laboratories. Corgenix offers over 50 diagnostic tests targeting immunology disorders, cardiovascular and vascular diseases, bone and joint disorders, and viral hemorrhagic diseases. Notable offerings include non-blood-based aspirin effect testing and multiple myeloma monitoring tools. The company provides comprehensive services across the IVD lifecycle: biomarker discovery, assay development, analytical and clinical validation, regulatory submissions, GMP manufacturing, quality control, and commercialization support. With an onsite CAP/CLIA laboratory, Corgenix supports clinical studies, trial management, physician-ordered patient testing, and research initiatives while maintaining strict regulatory compliance and GCP/GLP standards.

Tensentric is an ISO 13485:2016 certified engineering and manufacturing firm specializing in design, development, prototyping, and volume production of medical devices, in-vitro diagnostics (IVD), and life sciences systems. Founded in 2009 and headquartered in Boulder, Colorado, the company employs 83–96 engineers and scientists, many with over 20 years of experience across electromechanical systems, microfluidics, bioprocessing, and human factors optimization. With over 300 completed development projects and 75+ patents, Tensentric delivers turn-key system design from concept through volume manufacturing. Core competencies include custom-engineered instruments and consumables, point-of-care diagnostic platforms, cell and gene therapy bioprocessing equipment, and complex integrated systems for sample handling, biochemical analysis, and detection. Services encompass design and development, human factors and use-safety engineering, new product introduction (NPI), and dedicated manufacturing. Clients include Medtronic, BD, Philips, Johnson & Johnson, Stryker, and other major medtech OEMs. In 2022, the firm received strategic investment from GenNx360 Capital Partners to expand manufacturing and business development capabilities.

SeaStar Medical is a clinical-stage immunotherapy company developing the Selective Cytopheretic Device (SCD), a patented therapeutic platform designed to treat destructive hyperinflammatory responses in critically ill patients. The SCD selectively targets and neutralizes highly activated neutrophils and monocytes responsible for cytokine storms—uncontrolled inflammatory cascades triggered by trauma, infection, or surgery that can lead to multiorgan failure and death in ICU settings. The device integrates seamlessly into existing hemodialysis delivery systems, offering a disease-modifying approach to restore immune balance without requiring standalone infrastructure. SeaStar's technology addresses a significant clinical gap: there are currently no FDA-approved therapeutic options specifically designed to calm hyperinflammation in this patient population. The company's clinical evidence supports that SCD therapy may reduce ICU length of stay, decrease dialysis dependency, and improve survival outcomes. The device is positioned for use in critical care and intensive care units treating sepsis, post-surgical complications, and trauma-induced inflammatory responses. SeaStar Medical is headquartered in Denver, Colorado, and is focused on advancing the critical-care treatment paradigm through robust scientific validation and regulatory pathways.